Aromatase inhibitors: prediction of response and nature of resistance

Functional Genetic Polymorphisms in the Aromatase Gene CYP19 Vary the Response of Breast Cancer Patients to Neoadjuvant Therapy with Aromatase Inhibitors

(2010) L. Wang et al.   CANCER RESEARCH

Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer

(2009) Hiroko Yamashita et al.   CANCER SCIENCE

Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors

(2009) Philip Lazarus et al.   DRUG METABOLISM REVIEWS

Gene Expression Profiles Differentiating Between Breast Cancers Clinically Responsive or Resistant to Letrozole

(2009) William R. Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen

(2009) Mitch Dowsett et al.   JOURNAL OF CLINICAL ONCOLOGY

Rational management of endocrine resistance in breast cancer

(2008) Sara A. Hurvitz et al.   CANCER

Genome-Wide Analysis of Aromatase Inhibitor-Resistant, Tamoxifen-Resistant, and Long-Term Estrogen-Deprived Cells Reveals a Role for Estrogen Receptor

(2008) S. Masri et al.   CANCER RESEARCH

Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer

(2008) J Michael Dixon   Expert Review of Anticancer Therapy

Development of the 21-Gene Assay and Its Application in Clinical Practice and Clinical Trials

(2008) Joseph A. Sparano et al.   JOURNAL OF CLINICAL ONCOLOGY

Phosphorylated ERα, HIF-1α, and MAPK Signaling As Predictors of Primary Endocrine Treatment Response and Resistance in Patients With Breast Cancer

(2008) Daniele Generali et al.   JOURNAL OF CLINICAL ONCOLOGY

Aromatase Inhibitors: Are There Differences Between Steroidal and Nonsteroidal Aromatase Inhibitors and Do They Matter?

(2008) W. R. Miller et al.   ONCOLOGIST

Predicting response and resistance to endocrine therapy

(2007) William R. Miller et al.   CANCER